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Abstract
Chronic intestinal pseudo-obstruction (CIP) is an infre-
quent complication of an active systemic lupus erythema-
tosus (SLE). We illustrate a case of SLE inactive-related 
CIP. A 51-year old female with inactive SLE (ECLAM score 
2) was hospitalized with postprandial fullness, vomiting, 
abdominal bloating and abdominal pain. She had had no 
bowel movements for five days. Plain abdominal X-ray 
revealed multiple fluid levels and dilated small and large 
bowel loops with air-fluid levels. Intestinal contrast ra-
diology detected dilated loops. CIP was diagnosed. The 
patient was treated with prokinetics, octreotide, claritro-
mycin, rifaximin, azathioprine and tegaserod without any 
clinical improvement. Then methylprednisolone (500 mg 
iv daily) was started. After the first administration, the 
patient showed peristaltic movements. A bowel move-
ment was reported after the second administration. A 
plain abdominal X-ray revealed no air-fluid levels. Steroid 
therapy was slowly reduced with complete resolution of 
the symptoms. The patient is still in a good clinical condi-
tion. SLE-related CIP is generally reported as a complica-
tion of an active disease. In our case, CIP was the only 
clinical demonstration of the SLE. 
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune 
disease with a wide spectrum of  multisystemic presenta-
tions[1]. Chronic intestinal pseudo-obstruction (CIP) is a 
complication that usually occurs during active SLE and 
is characterised by ineffective intestinal propulsion with-
out any mechanical obstruction of  the gut[2]. It is caused 
by the involvement of  visceral smooth muscle and en-
teric nervous system and can be further classified as idi-
opathic or secondary. A secondary CIP can be induced 
by neurological, muscular, endocrine, metabolic and con-
nective tissue diseases, infective agents and drugs[3].
CASE REPORT
A 51-year old female with a 13-year history of  SLE (ACR 
criteria 1997) and nephrotic syndrome was hospitalized 
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after the onset of  postprandial fullness with vomiting, ab-
dominal bloating, dysphagia with solid foods and abdomi-
nal pain with cramps. She had had no bowel movements 
for five days. 
Physical examination disclosed abdominal tenderness 
and distended abdomen with absent bowel sounds. She 
had been unsuccessfully treated with common prokinet-
ics at the maximum dosage. Nasogastric probe and rectal 
tube were positioned. Cyclosporine (5 mg/kg per day), 
esomeprazole (40 mg daily), rifaximin (600 mg daily) and 
gentle enemas were started. 
Blood tests showed slight anemia and leukopenia with 
reduction of  serum proteins. Plasmatic levels of  RCP, 
ERV, IgG and IgA were increased. The other laboratory 
tests were normal including urea nitrogen, creatinine, C3, 
C4 and CH50.
An upper digestive endoscopy was performed which 
detected esophagitis grade A according to the Los Ange-
les Classification and antral gastritis (H.P. negative).
Plain abdominal X-ray revealed multiple fluid levels 
and dilated small and large bowel loops with air-fluid 
levels. Ultrasound scan and abdominal computed tomog-
raphy scan showed gastric distension and circumferential 
thickening of  the large bowel without mechanical obstruc-
tion. Intestinal contrast radiology with soluble material 
detected dilated loops with very slow transit. Esophageal 
and ano-rectal manometry were performed to rule out 
scleroderma and Hirschsprung’s disease respectively.
On the basis of  these findings, chronic intestinal pseu-
do-obstruction was suspected and the patient was treated 
with octreotide (50 mg daily), clarithromycin (500 mg daily), 
rifaximin (1200 mg daily) and azathioprine (100 mg daily) 
without any clinical improvement. Tegaserod (6 mg bid) 
was also added without any positive effect.
Then an intravenous bolus of  methylprednisolone (500 
mg daily) was planned for three days. Quickly after the 
first administration the patient reported peristaltic move-
ments. A bowel movement was reported after the second 
administration and a plain abdominal X-ray revealed no 
air-fluid levels. After the third bolus of  500 mg, it was 
decided to decrease the methylprednisolone to 100 mg iv 
daily for a week. After a few days, the abdominal tender-
ness and distension completely disappeared and abdomi-
nal sounds were clearly present. Over the next weeks, the 
steroid therapy was slowly but constantly reduced with a 
good response and a complete resolution of  the symp-
toms. The patient is still in a good clinical condition.
DISCUSSION
SLE can involve each part of  the gastrointestinal tract with 
oral aphthosis, esophageal dysmotility, mesenteric vasculitis, 
protein-losing enteropathy and pancreatitis as the most fre-
quent manifestations[4]. Gastrointestinal involvement in SLE 
is rare. Apart from the mucosal involvement, the frequency 
of  GI manifestations is very low.
CIP has been recognized as an uncommon and poorly 
understood complication of  SLE: it usually occurs dur-
ing active lupus (it can appear as a complication or as the 
initial presentation of  SLE) but may manifest itself  in in-
active lupus. Until now, only 27 cases of  SLE related CIP 
have been reported in literature[2].
This is the only SLE-related case of  CIP in our experi-
ence. We started to treat the patient for a motility intesti-
nal disorder because, on the basis of  the clinical and se-
rological criteria, the disease was inactive (ECLAM score 
2)[5]. After the failure of  a targeted motility approach, we 
considered the autoimmune disease as the core of  the 
problem and the patient was successfully given a steroid 
therapy. SLE-related CIP, generally unusual, is reported 
as a complication of  an active disease and favourably 
responds to high doses of  corticosteroids[6]. In our case, 
CIP was the only clinical demonstration of  the SLE.
Also, in inactive SLE, it is mandatory to start steroid 
therapy when CIP fails to respond to a targeted motility 
therapy. 
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